文献速递白血病淋巴瘤

DNTT介导的DNA损伤反应驱动B细胞急性淋巴细胞白血病对奥加伊妥珠单抗的耐药

DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia.
PubMed 文献 · Blood · 2025-01-01

本研究通过全基因组CRISPR筛选发现,DNA核苷酸转移酶(DNTT)缺失是B细胞急性淋巴细胞白血病(B-ALL)对奥加伊妥珠单抗(InO)耐药的主要驱动因素。DNTT下调可减弱InO诱导的DNA损伤反应、细胞周期阻滞和线粒体凋亡 priming,导致白血病耐药。在儿童肿瘤组AALL1621试验患者中,InO治疗后残留原始细胞出现一致的DNTT下调,患者来源异种移植模型也重现了InO对DNTT低表达原始细胞的选择。

要点

  • 全基因组CRISPR筛选发现DNTT缺失是InO耐药的主要驱动因素。
  • DNTT下调减弱InO诱导的DNA损伤反应、细胞周期阻滞和线粒体凋亡 priming。
  • InO治疗后B-ALL患者残留原始细胞及PDX模型中DNTT下调被选择。

核心结论

  • DNTT是白血病对卡奇霉素反应的关键调节因子,可能是B-ALL中个体化InO治疗的潜在生物标志物。

研究设计与样本

  • 研究采用全基因组CRISPR筛选,并结合B-ALL患者样本、单细胞RNA测序及患者来源异种移植模型进行验证。
  • 在儿童肿瘤组AALL1621试验中纳入的B-ALL患者中观察了InO治疗前后残留原始细胞的DNTT表达。

主要发现

  • 全基因组CRISPR筛选发现DNTT缺失是InO耐药的主要驱动因素。
  • DNTT下调减弱InO诱导的DNA损伤反应、细胞周期阻滞和线粒体凋亡 priming,最终导致白血病对InO耐药。
  • 单细胞RNA测序显示白血病原始细胞对InO的体外敏感性与DNTT表达高度相关,且白血病内部存在显著异质性。
  • 在儿童肿瘤组AALL1621试验的B-ALL患者中,InO治疗后残留原始细胞观察到一致的DNTT下调。
  • InO治疗对DNTT低表达原始细胞的选择在患者来源异种移植模型中体内重现。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Inotuzumab ozogamicin (InO) is an antibody-calicheamicin conjugate with striking efficacy in B-cell acute lymphoblastic leukemia (B-ALL). However, there is wide interpatient variability in treatment response, and the genetic basis of this variation remains largely unknown. Using a genome-wide CRISPR screen, we discovered that the loss of DNA nucleotidylexotransferase (DNTT) is a primary driver of InO resistance. Mechanistically, the downregulation of DNTT attenuated InO-induced DNA damage response, cell cycle arrest, and mitochondrial apoptotic priming, thereby ultimately leading to leukemia resistance to InO. Ex vivo leukemia InO sensitivity was highly associated with DNTT expression in ALL blasts with substantial intraleukemia heterogeneity as revealed by single-cell RNA sequencing. Among patients with B-ALL enrolled in the Children's Oncology Group trial AALL1621, we observed consistent DNTT downregulation in residual blasts following InO treatment. The selection of DNTT-low blasts by InO therapy was also recapitulated in vivo using patient-derived xenograft models. Collectively, our data indicate that DNTT is a key regulator of calicheamicin response in leukemia and thus a potential biomarker for individualizing InO therapy in B-ALL.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Escherich CS, Moriyama T, Li Z, et al. DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia. Blood. 2025. PMID: 39791601. doi:10.1182/blood.2024026085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。